Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan

被引：0
|
作者：
Gonzalez-Baron, M. [1 ]
Blanco, M. [1 ]
Feliu, J. [1 ]
Gomez, C. [1 ]
Casado, E. [1 ]
Castro, J. [1 ]
Belda-Iniesta, C. [1 ]
Garrido, M. [1 ]
Aguayo, C. [1 ]
Campos, M. A. [1 ]
机构：
[1] Hosp La Paz, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14600
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer
    Khayat, D
    Gil-Delgado, M
    Antoine, EC
    Nizri, D
    Bastian, G
    ONCOLOGY-NEW YORK, 2001, 15 (04): : 415 - 429
  • [42] Becam: A salvage protocol with bevacizumab, capecitabin, and mitomycin C for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
    Peinert, SP
    Grothe, WG
    Kuehne, IK
    Kegel, TK
    Arnold, DA
    Schmoll, HJS
    ANNALS OF ONCOLOGY, 2006, 17
  • [43] Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer
    Cao, SS
    Bhattacharya, A
    Durrani, FA
    Fakih, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 687 - 703
  • [44] Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
    Peinert, S.
    Arnold, D.
    Grothe, W.
    Lesske, J.
    Siewczynski, R.
    Schaedlich, B.
    Kegel, T.
    Behrmann, C.
    Schmoll, H.-J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [45] The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer
    Poston, GJ
    EJSO, 2005, 31 (04): : 325 - 330
  • [46] Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer
    Jehn, C. F.
    Boening, L.
    Kroening, H.
    Pezzutto, A.
    Lueftner, D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) : 1269 - 1275
  • [47] Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial
    Lipsyc-Sharf, Marla
    Ou, Fang-Shu
    Yurgelun, Matthew B.
    Rubinson, Douglas Adam
    Schrag, Deborah
    Dakhil, Shaker R.
    Stella, Philip J.
    Weckstein, Douglas Jay
    Wender, Donald B.
    Faggen, Meredith Gail
    Zemla, Tyler
    Heying, Erica N.
    Schuetz, Samantha R.
    Noble, Stephanie
    Meyerhardt, Jeffrey A.
    Bekaii-Saab, Tanios S.
    Fuchs, Charles S.
    Ng, Kimmie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [48] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    Sobrero, Alberto F.
    Maurel, Joan
    Fehrenbacher, Louis
    Scheithauer, Werner
    Abubakr, Yousif A.
    Lutz, Manfred P.
    Vega-Villegas, M. Eugenia
    Eng, Cathy
    Steinhauer, Ernst U.
    Prausova, Jana
    Lenz, Heinz-Josef
    Borg, Christophe
    Middleton, Gary
    Kroening, Hendrik
    Luppi, Gabriele
    Kisker, Oliver
    Zubel, Angela
    Langer, Christiane
    Kopit, Justin
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
  • [49] Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer
    Lee, F.
    Roach, M.
    Duong, L.
    Heywood, G.
    Parasher, G.
    Rasila, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    Campbell, Jenny C.
    Shah, Manish A.
    Capanu, Marinela
    Kelsen, David P.
    Ilson, David H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 126 - 130
12345